<description>&lt;p&gt;What can a tiny worm tell us about human ageing, and could gut bacteria hold the key to a longer, healthier life?&lt;/p&gt;&lt;p&gt;In this episode of &lt;em&gt;Beyond Longevity&lt;/em&gt;, we sit down with Professor David Weinkove: Chair of the British Society for Research on Ageing (BSRA), Professor at Durham University, and Co-founder and CSO of Magnitude Biosciences. David's lab uses the short-lived nematode &lt;em&gt;C. elegans&lt;/em&gt; to run fast, rigorous experiments looking for interventions that extend healthspan and lifespan, and the results are pointing in some surprising directions.&lt;/p&gt;&lt;p&gt;We cover how Prof David moved from physics into experimental molecular biology, how his team discovered that bacterial strains and metabolites can dramatically alter how long worms stay active, and what inhibiting bacterial folate synthesis reveals about the biology of ageing. He also explains how worm movement is a practical proxy for healthspan and why that matters for scaling up research.&lt;/p&gt;&lt;p&gt;The conversation gets into the thornier questions, too: when do you need mice, and when might you skip straight to human-relevant models? How do you fund prevention research when the payoff is decades away? And what are the real risks of mandatory folic acid flour fortification, a policy Prof David argues deserves more scrutiny, given potential microbiome effects we don't yet fully understand.&lt;/p&gt;&lt;p&gt;Prof David also unpacks what the BSRA does day-to-day: from connecting researchers and lobbying government to running small grants and building bridges with clinicians and industry, and why he thinks the longevity field's biggest enemy isn't scepticism, it's overpromising.&lt;/p&gt;&lt;p&gt;Plus, we discover the most extreme longevity idea he's ever come across (involving spare parts — we'll leave it there).&lt;/p&gt;&lt;p&gt;Links:&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.durham.ac.uk/staff/david-weinkove/" rel="noopener noreferrer" target="_blank"&gt;https://www.durham.ac.uk/staff/david-weinkove/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://magnitudebiosciences.com/" rel="noopener noreferrer" target="_blank"&gt;Home - Magnitude Biosciences&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://bsra.org.uk/" rel="noopener noreferrer" target="_blank"&gt;HOME PAGE - BSRA&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.linkedin.com/in/david-weinkove-bab807b" rel="noopener noreferrer" target="_blank"&gt;https://www.linkedin.com/in/david-weinkove-bab807b&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;&lt;strong&gt;In this episode:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;00:00 Welcome to Beyond Longevity + Meet Prof. David Weinkove&lt;/p&gt;&lt;p&gt;02:40 From Physics to Bioscience: Career Origins &amp;amp; Model Organisms&lt;/p&gt;&lt;p&gt;04:29 The Breakthrough: How Bacteria (and Folate) Can Extend Worm Lifespan&lt;/p&gt;&lt;p&gt;09:12 Measuring Healthspan in C. elegans: Movement, Decline &amp;amp; New Tech&lt;/p&gt;&lt;p&gt;10:38 Why C. elegans? Fast Ageing, Whole-Organism Biology &amp;amp; Screening Power&lt;/p&gt;&lt;p&gt;12:19 Worms vs Mice: Similarity to Humans, Ethics, Cost &amp;amp; Experimental Variability&lt;/p&gt;&lt;p&gt;15:35 Translating Worm Findings to Humans: Microbiome Links, Exercise Paper &amp;amp; Next Steps&lt;/p&gt;&lt;p&gt;17:52 Funding the Science: UKRI, MRC vs BBSRC, and the Reality of Grant Constraints&lt;/p&gt;&lt;p&gt;20:52 Why Longevity Research Struggles for Support: Messaging, Hype &amp;amp; Prevention&lt;/p&gt;&lt;p&gt;28:39 BSRA’s Mission &amp;amp; the Five Pillars: Public Engagement, Advocacy, Fundraising, Translation&lt;/p&gt;&lt;p&gt;32:01 Breaking Down Silos: Making Longevity Research Useful (and Public)&lt;/p&gt;&lt;p&gt;34:07 Prevention Mindset: Why “Healthier for Longer” Isn’t Instant Gratification&lt;/p&gt;&lt;p&gt;36:15 When to Start Interventions: Metformin, Timing, and Trial Design Challenges&lt;/p&gt;&lt;p&gt;39:39 Why Magnitude Bioscience Exists: Fast Whole-Organism Ageing Screens&lt;/p&gt;&lt;p&gt;41:12 What Companies Test in Worms: From Candidate Drugs to 1,000-Compound Screens&lt;/p&gt;&lt;p&gt;42:48 Folic Acid Fortification &amp;amp; the Microbiome: A Potential Unintended Consequence&lt;/p&gt;&lt;p&gt;45:55 Should Government Engineer Health? Autonomy, Risk, and Public Policy Trade-offs&lt;/p&gt;&lt;p&gt;52:37 Ageing Demographics &amp;amp; the Case for Prevention-First Healthcare Investment&lt;/p&gt;&lt;p&gt;55:59 Making Longevity Matter to Everyday People + Rapid-Fire Q&amp;amp;A&lt;/p&gt;&lt;p&gt;01:01:47 Final Takeaways, Thanks, and Episode Wrap-Up&lt;/p&gt;</description>

Beyond Longevity

Daphna Stern

Professor David Weinkove, Chair of the BSRA, on C.elegans research and evidence-led longevity science

FEB 22, 202663 MIN
Beyond Longevity

Professor David Weinkove, Chair of the BSRA, on C.elegans research and evidence-led longevity science

FEB 22, 202663 MIN

Description

What can a tiny worm tell us about human ageing, and could gut bacteria hold the key to a longer, healthier life?In this episode of Beyond Longevity, we sit down with Professor David Weinkove: Chair of the British Society for Research on Ageing (BSRA), Professor at Durham University, and Co-founder and CSO of Magnitude Biosciences. David's lab uses the short-lived nematode C. elegans to run fast, rigorous experiments looking for interventions that extend healthspan and lifespan, and the results are pointing in some surprising directions.We cover how Prof David moved from physics into experimental molecular biology, how his team discovered that bacterial strains and metabolites can dramatically alter how long worms stay active, and what inhibiting bacterial folate synthesis reveals about the biology of ageing. He also explains how worm movement is a practical proxy for healthspan and why that matters for scaling up research.The conversation gets into the thornier questions, too: when do you need mice, and when might you skip straight to human-relevant models? How do you fund prevention research when the payoff is decades away? And what are the real risks of mandatory folic acid flour fortification, a policy Prof David argues deserves more scrutiny, given potential microbiome effects we don't yet fully understand.Prof David also unpacks what the BSRA does day-to-day: from connecting researchers and lobbying government to running small grants and building bridges with clinicians and industry, and why he thinks the longevity field's biggest enemy isn't scepticism, it's overpromising.Plus, we discover the most extreme longevity idea he's ever come across (involving spare parts — we'll leave it there).Links:https://www.durham.ac.uk/staff/david-weinkove/Home - Magnitude BiosciencesHOME PAGE - BSRAhttps://www.linkedin.com/in/david-weinkove-bab807b In this episode:00:00 Welcome to Beyond Longevity + Meet Prof. David Weinkove02:40 From Physics to Bioscience: Career Origins & Model Organisms04:29 The Breakthrough: How Bacteria (and Folate) Can Extend Worm Lifespan09:12 Measuring Healthspan in C. elegans: Movement, Decline & New Tech10:38 Why C. elegans? Fast Ageing, Whole-Organism Biology & Screening Power12:19 Worms vs Mice: Similarity to Humans, Ethics, Cost & Experimental Variability15:35 Translating Worm Findings to Humans: Microbiome Links, Exercise Paper & Next Steps17:52 Funding the Science: UKRI, MRC vs BBSRC, and the Reality of Grant Constraints20:52 Why Longevity Research Struggles for Support: Messaging, Hype & Prevention28:39 BSRA’s Mission & the Five Pillars: Public Engagement, Advocacy, Fundraising, Translation32:01 Breaking Down Silos: Making Longevity Research Useful (and Public)34:07 Prevention Mindset: Why “Healthier for Longer” Isn’t Instant Gratification36:15 When to Start Interventions: Metformin, Timing, and Trial Design Challenges39:39 Why Magnitude Bioscience Exists: Fast Whole-Organism Ageing Screens41:12 What Companies Test in Worms: From Candidate Drugs to 1,000-Compound Screens42:48 Folic Acid Fortification & the Microbiome: A Potential Unintended Consequence45:55 Should Government Engineer Health? Autonomy, Risk, and Public Policy Trade-offs52:37 Ageing Demographics & the Case for Prevention-First Healthcare Investment55:59 Making Longevity Matter to Everyday People + Rapid-Fire Q&A01:01:47 Final Takeaways, Thanks, and Episode Wrap-Up